The free dividend tracker to help you grow your wealth. Link your brokerage accounts and MerryDiv automatically syncs your holdings and dividends.
Data last updated: Sep 14, 2026
Snapshot (as of Sep 14, 2026): iShares Biotechnology ETF (IBB) pays a $0.41 annual dividend ($0.10 quarterly), yielding 0.20% at $202.93/share. Next ex-dividend date 2026-06-15. Source: Yahoo Finance, aggregated by MerryDiv.
Dividend Yield: 0.20%
Annual Dividend: $0.41 per share
Ex-Dividend Date: 2026-06-15
Dividend Frequency: quarterly
Sector: Financial Services
Years of Dividend History: 20
The iShares Biotechnology ETF dividend reflects a fund built to track U.S. biotechnology stocks, giving investors exposure to one of the more volatile corners of the equity market. IBB currently yields 0.2%, with a trailing annual dividend rate of $0.4115 per share paid quarterly. The next ex-dividend date is June 15, 2026. With a beta of 0.713, the fund moves with less volatility than the broader market, which suits investors who want biotech exposure without the full swing of individual stock risk.
iShares Biotechnology ETF pays out dividends as a pass-through from its underlying holdings, a payout ratio classified as not applicable (fund/ETF). The dividend amount IBB distributes each quarter depends directly on the income generated by its portfolio of U.S. biotechnology stocks, so iShares Biotechnology ETF dividend safety is tied to the income activity of those holdings rather than a corporate earnings floor. The most significant pressure on the payout is the variability in distributions across the historical record, with year-over-year swings exceeding 50% in multiple periods.
iShares Biotechnology ETF dividend history shows a CAGR of -5.6% per year from 2012 to 2023. Per-share payouts moved from $0.6566 in 2012 to $0.3480 in 2023, a net decline over the full window (2026 data is partial and excluded from this calculation). The largest single-year increase in the window was 46.0% in 2017, but that spike did not offset the broader downward drift, and the fund has posted only 2 consecutive years of dividend increases as of the most recent complete data.
| Period | CAGR | From | To |
|---|---|---|---|
| 3-Year | -1.8% | $0.41 (2022) | $0.39 (2025) |
| 5-Year | +4.5% | $0.31 (2020) | $0.39 (2025) |
| 10-Year | +15.4% | $0.09 (2015) | $0.39 (2025) |
IBB fits dividend investors who treat the income as secondary to biotech sector exposure. The yield is low (below 2%), currently at 0.2%, which is only marginally above its 5-year average of 0.18%. That narrow gap means the current payout is not offering a meaningful premium over what the fund has historically delivered. The CAGR of -5.6% per year from 2012 to 2023 is a real headwind for income-focused investors. What an investor gets is biotech index exposure with a beta of 0.713 and a modest income stream. The trade-off is a shrinking dividend trend and a yield too low to anchor an income portfolio.
| Payment Date | Amount per Share |
|---|---|
| 2026-06-15 | $0.0238 |
| 2026-03-17 | $0.1218 |
| 2025-12-16 | $0.1831 |
| 2025-09-16 | $0.0828 |
| 2025-03-18 | $0.1212 |
| 2024-12-17 | $0.0624 |
| 2024-09-25 | $0.2005 |
| 2024-03-21 | $0.1260 |
| 2023-12-20 | $0.1240 |
| 2023-09-26 | $0.1532 |
| Year | Total Dividends |
|---|---|
| 2026 | $0.1456 |
| 2025 | $0.3871 |
| 2024 | $0.3889 |
| 2023 | $0.3480 |
| 2022 | $0.4090 |
Project income from IBB with the IBB dividend calculator or track your full portfolio with the dividend tracker.